| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 21.6 | 13.1 |
| Gross profit | 16.7 | 9.9 |
| Net income | -12.2 | -8.5 |
| EPS (diluted, $ a share) | $-0.45 | $-0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +64.9% |
|---|---|
| Gross margin | 77.3% |
| Operating margin | -58.9% |
10-Q filed with the SEC, NASDAQ: CARL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Carlsmed, Inc.: key numbers
- Share price
- $17.35Close, Nov 16
- Market cap
- $475M
- Shares outstanding
- 27.4MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Carlsmed, Inc.
All →Carlsmed Financial Results
Carlsmed reported Q3 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by a 60% expansion of its surgeon user base. The company raised its full-year 2026 revenue guidance to $78-$80 million and highlighted new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure.
- Term
- Q3 2026
“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year.”
Mike Cordonnier, Chairman and CEO
“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”
Mike Cordonnier, Chairman and CEO
Carlsmed COO Jeffrey Bertolini Sells $11.3K of Stock
Jeffrey Bertolini, COO, sold 747 shares of Carlsmed, Inc. at $15.15 a share, worth $11.3K in total on Nov 3, 2026. Shares held after the trade: 22,489 (-3.2%).
- Value
- $11.3K
- Shares
- 747
- Price
- $15.15
- Role
- COO
- Holding change
- -3.2%
- Trade date
- Nov 3, 2026
Carlsmed COO Jeffrey Bertolini Sells $10.7K of Stock
Jeffrey Bertolini, COO, sold 747 shares of Carlsmed, Inc. at $14.39 a share, worth $10.7K in total on Oct 5, 2026. Shares held after the trade: 22,489 (-3.2%).
- Value
- $10.7K
- Shares
- 747
- Price
- $14.39
- Role
- COO
- Holding change
- -3.2%
- Trade date
- Oct 5, 2026
Carlsmed Leadership Change
Carlsmed appointed Richard Heppenstall as Chief Financial Officer, effective September 28, 2026, succeeding Leo Greenstein who departed the role. Mr. Greenstein will receive a $500,000 cash severance payment and accelerated equity vesting, while also serving as an advisor through the end of 2026. The company reaffirmed its full-year 2026 revenue guidance of $74 million to $78 million in conjunction with the transition.
- Counterparty
- Richard Heppenstall